Krina K. Patel, MD, MSc

Peer-Reviewed Articles

1. Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma (RRMM): Real-world Experience from the Myeloma CAR T Consortium. J Clin Oncol 41(11):2087-2097, 2023. e-Pub 2023. PMID: 36623248.
2. Brian T. Hess, Anshu Giri, Yeonhee Park, Krina K. Patel, Brian K. Link, Grzegorz S. Nowakowski, Seth M. Maliske, Sonia Fortin, Julio C. Chavez, Hayder Saeed, Brian T. Hill, Alex V. Mejia Garcia, Kami J. Maddocks, Walter Hanel, Nina D. Wagner-Johnston, Marcus R. Messmer, Brad S. Kahl, Marcus Watkins, Juan Pablo Alderuccio, Izidore S. Lossos, Sunita Nathan, Victor M. Orellana-Noia, Craig A. Portell, Daniel J. Landsburg, Emily C. Ayers, Jorge J. Castillo. Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. American Journal of Hematology, 2023. PMID: 36588409.
3. Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance,. Leuk Lymphoma 63(3):710-721, 2022. e-Pub 2021. PMID: 34686083.
4. Krina K. Patel, Jatin J. Shah, Lei Feng, Hans C. Lee, Elisabet E. Manasanch, Jasper Olsem, Ashley Morphey, Xiao Jiao Huo, Sheeba K. Thomas, Qaiser Bashir, Muzaffar H. Qazilbash, Donna M. Weber, and Robert Z. Orlowski. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-transplant Myeloma Patients. Clinical Cancer Research, 2022.
5. Manasanch EE, Mulanovich V, Manzano JG, Gaeta MS, Becnel M, Kaufman GP, Lee HC, Amini B, Thomas SK, Iyer SP, Weber DM, Berkova Z, Flowers CR, Orlowski RZ, Patel KK. SARS-CoV-2 in multiple myeloma: initial observation and management. Leuk Lymphoma 61(11):2763-2766, 2020. e-Pub 2020. PMID: 33167721.
6. Chaudhry M, Steiner R, Claussen C, Patel K, Lee H, Weber D, Thomas S, Feng C, Amini B, Orlowski R, Feng L, Manasanch EE. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia. Leuk Lymphoma 60(4):1-7, 2019. e-Pub 2018. PMID: 30227761.
7. Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma 60(2):1-11, 2019. e-Pub 2018. PMID: 30032678.
8. Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant 53(3):315-325, 2018. e-Pub 2017. PMID: 29269797.
9. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma 59(2):515-518, 2018. e-Pub 2017. PMID: 28673185.
10. Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer 123(18):3568-3575, 2017. e-Pub 2017. PMID: 28513828.
11. Khouri MR, Jabbour EJ, Gulbis AM, Turturro F, Ledesma C, Korbling M, Samuels BI, Ahmed S, Alousi AM, Ciurea SO, Marin D, Patel KK, Popat UR, Bueso-Ramos CE, Bassett RL, Khouri IF. Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. Biol Blood Marrow Transplant 23(8):1405-1410, 2017. e-Pub 2017. PMID: 28495642.
12. Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol 4(6):e283-e292, 2017. e-Pub 2017. PMID: 28522110.
13. Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol 177(3):457-466, 2017. e-Pub 2017. PMID: 28295190.
14. Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant 23(2):285-292, 2017. e-Pub 2016. PMID: 27816651.
15. Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 22(12):2159-2164, 2016. e-Pub 2016. PMID: 27638366.
16. Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Systemic Light chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. Eur J Haematol 97(4):342-7, 2016. e-Pub 2016. PMID: 26773409.
17. Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash MH. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol 91(10):E442-7, 2016. e-Pub 2016. PMID: 27420405.
18. Khouri IF, Sui D, Jabbour EJ, Samuels BI, Turturro F, Alatrash G, Anderlini P, Ahmed S, Oran B, Ciurea SO, Marin D, Olson A, Patel KK, Popat UR, Ledesma C, Kadia TM, Ferrajoli A, Burger JA, Jorgensen JL, Medeiros LJ, Bassett RL, Gulbis AM. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplant. e-Pub 2016. PMID: 27595282.
19. Sasaki K, Popat U, Jain P, Kadia T, Patel K, Patel K, Jain N, Takahashi K, Young K, Miranda RN, Oo TH, Lu H, Pemmaraju N. Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. Clin Case Rep 4(8):765-7, 2016. e-Pub 2016. PMID: 27525080.
20. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk 16(3):122-8, 2016. e-Pub 2015. PMID: 26795083.
21. Patel K, Nusrat M, Shah N, Bashir Q, Parmar S, Shah J, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MH. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone Marrow Transplant 49(3):465-6, 2014. e-Pub 2014. PMID: 24419515.
22. Menon C, Bauer TW, Kelley ST, Raz DJ, Bleier JI, Patel K, Steele K, Prabakaran I, Shifrin A, Buerk DG, Sehgal CM, Fraker DL. Tumoricidal activity of high-dose tumor necrosis factor-alpha is mediated by macrophage-derived nitric oxide burst and permanent blood flow shutdown. Int J Cancer 123(2):464-75, 2008. PMID: 18449880.

Other Articles

1. Patel K NEJM Knowledge+ Oncology, 2013.

Abstracts

1. Qazilbash MH, Bashir Q, Thall PF, Milton DR, Shah N, Patel KK, Andersson BS, Nieto Y, Kebriaei P, Valdez BC, Kawedia J, Parmar S, Delgado R, Ahmed S, Hosing C, Popat U, Shpall EJ, Weber DM, Thomas SK, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE. #399 A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma. Blood 2017 ASH 130, 2017. e-Pub 2017.
2. Patel KK, Shah JJ, Feng L, Lee HC, Manasanch EE, Thomas SK, Weber DM, Munoz SC, Morphey A, Bashir Q, Qazilbash MH, Orlowski RZ. #437 Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood ASH 2017 130, 2017. e-Pub 2017.
3. Mathur R, Zhang Z, He J, Galetto R, Gouble A, Chion-Sotinel I, Filipe S, Gariboldi A, Veeramachaneni T, Manasanch EE, Thomas SK, Lee HC, Patel KK, Weber DM, Davis RE, Orlowski RJ, Smith J, Yang J, Neelapu SS. #502 Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple. Blood ASH 2017 130, 2017.
4. Thomas SK, Shah JJ, Lee HC, Manasanch EE, Weber DM, Patel KK, Feng L, Amini B, Morphey A, Crumpton B, Phillips S, Miller C, Gonzalez M, Orlowski RZ. #840 Preliminary Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Mutliple Myeloma. Blood ASH 2017 130, 2017.
5. Chaudhry M, Steiner R, Claussen CM, Patel K, Lee HC, Weber DM, Thomas SK, Feng C, Kramer M, Amini B, Orlowski RZ, Feng L, Manasanch EE. #1880 Carfilzomib-Based Combination Regimens Are Highly Effective Frontline Therapies for multiple Myeloma and WaldenstroM's Macroglobulinemia. Blood ASH 2017 130, 2017.
6. Mathur R, Barnett Be, Hermanson D, He J, Zhang Z, Rengarajan S, Codde R, Wang X, Tan Y, Martin C, Smith J, Lee HC, Manasanch EE, Thomas SK, Patel KK, Weber DM, Davis RE, Orlowski RZ, Ostertag EM, Shedlock D, Yang J, Neelapu SS. #3068 B-Cell Maturation Antigen (BCMA)-Specific, CentyrinTM-Based, PiggyBacTM-Transposed CAR-T Memory Stem Cells Are Effective Against p53-/- and Patient-Derived Multiple Myeloma Tumors. Blood ASH 2017 130, 2017.
7. Manasanch EE, Mathur R, Lee HC, Weber DM, Patel KK, Thomas SK, Munoz SC, de Partovi CM, Claussen CM, Lin P, Amini B, Wang L, MA MCJ, Qing Y, Lei F, Baladandayuthapani V, Davis RE, Neelapu SS, Orlowski RZ. #3089 Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma. Blood ASH 2017 130, 2017.
8. Manasanch EE, Lee HC, Patel KK, Weber DM, Lee HJ, Thomas SK, Chen W, Oriabure O, Badillo M, Graham V, Lei F, McCarthy MS, Orlowski RZ, Wang M. #3090 A Phase I/II Study of Pomalidomide and Dexamethasone with Growth Factor Support in Patients with Relapsed/Refractory Multiple Myeloma. Blood ASH 2017 130, 2017.
9. Qazilbash MH, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross B, Honhar M, Cha S, Kim K, Popescu M, Shah N, Bashir Q, Patel KK, Lee VY, Shpall EJ, Weber DM, Thomas SK, Orlowski RZ, Kerr N, Garfall AL, Cohen AD, Vogl DT, Dengel K, June CH, Champlin RE, Kwak LW. #3193 Randomized Phase II Trial of Combination Idiotype Vaccine and Adoptive Cell Transfer of Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. Blood ASH 2017 130, 2017.
10. Claussen CM, Chuang T, Chaudhry M, Lee HC, Patel KK, Bashir Q, Parmar S, Ahmed S, Mehta RS, Thomas SK, Richards TA, Nieto Y, Shpall EJ, Qazilbash MH, Amini B, Davis RE, Neelapu SS, Weber DM, Orlowski RZ, Feng L, Manasanch EE. #4365 Gene Expression Profiling Is a Strong Predictor of Clinical Outcomes in Newly Diagnosed Multiple Myeloma. Blood ASH 2017 130, 2017.
11. Basir Q, El Shazly M, Milton DR, Patel K, Shah N, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea SO, Hosing C, Lee H, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash M. Outcome of Autologous Stem Cell Transplantation in Myeloma Patients Aged ≥ 75 Years. Blood ASH 2016 128(22):3453. e-Pub 2016.
12. Cerrada SL, Marin D, Rondon G, Ledesma C, Popat UR, Olson AL, Alousi AM, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Rezvani K, Jabbour E, Kantarjian HM, Champlin RE, Kebriaei P. Impact of New Anti-Leukemia Agents on Transplant Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in Second Complete Remission. Blood ASH 2016 128(22):4676, 2016. e-Pub 2016.
13. Cerrada SL, Marin D, Rondon G, Ledesma C, Popat UR, Olson A, Alousi A, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Rezvani K, Jabbour E, Kantarjian HM, Champlin RE, Kebriaei P. Additional Consolidation after Attaining Second Complete Remission Results in Superior Outcomes after Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. Blood ASH 2016 128(22):4680, 2016. e-Pub 2016.
14. Claussen CM, Lee H, Shah JJ, Richards T, Shah N, Patel K, Bashir Q, Parmar S, Thomas S, Nieto Y, Qazilbash MH, Davis RE, Neelapu SS, Weber DM, Orlowski RZ, Feng L, Manasanch EE. Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. Blood ASH 2016 128(22):5628, 2016. e-Pub 2016.
15. Cornelison AM, Saliba RM, Ahmed S, Nieto Y, Bashir Q, Shah N, Parmar S, Patel K, Hosing C, Popat UR, Shpall EJ, Champlin RE, Qazilbash MH. Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. Blood ASH 2016 128(22):5884, 2016. e-Pub 2016.
16. Kebriaei P, Wei W, Thall PF, Ledesma C, Valdez BC, Popat UR, Olson AL, Alousi AM, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Marin D, Rezvani K, Nieto Y, Champlin RE, Andersson BS. Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia. Blood ASH 2016 128(22):64, 2016. e-Pub 2016.
17. Qazilbash MH, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross BM, Honhar M, Cha SC, Kim K, Rao SS, Popescu M, Shah N, Bashir Q, Patel K, Shpall EJ, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Kerr NDS, Garfall AL, Cohen AD, Dengel K, June CH, Champlin RE, Kwak L. Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. Blood ASH 2016 128(22):4548, 2016. e-Pub 2016.
18. Mohyuddin GR, Faisal MS, Shah N, Bashir Q, Hosing C, Patel K, Popat UR, Parmar S, Rondon G, Delgado R, Weber DM, Shah JJ, Thomas S, Manasanch EE, Orlowski RZ , Champlin RE, Qazilbash MH. A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson. Blood ASH 2016 128(22):4613, 2016. e-Pub 2016.
19. Srour SA, Saliba RM, Delgado R, Qazilbash MH, Bashir Q, Shah N, Popat UR, Ahmed S, Patel K, Jones R, Rondon G, Champlin RE, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Blood ASH 2016 128(22):3314, 2016. e-Pub 2016.
20. Patel K, Olivares S, Singh H, Hurton LV, Huls MH, Qazilbash MH, Kebriaei P, Champlin RE, Cooper LJN. Combination Immunotherapy with NY-ESO-1-Specific CAR+ T Cells with T-Cell Vaccine Improves Anti-Myeloma Effect. Blood ASH 2016 128(22):3366, 2016. e-Pub 2016.
21. Veltri LW, Milton DR, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea SO, Hosing C, Lee H, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcome of Autologous Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Multiple Myeloma. Blood ASH 2016 128(22):4626, 2016. e-Pub 2016.
22. Patel KK, Shah S, Arrigain S, Jolly S, Schold J, Navaneethan S, Griffin BP, Nally JV, Desai MY. Abstract 18425: Characteristics and Outcomes of Patients With Aortic Stenosis and Chronic Kidney Disease Not on Dialysis. Circulation 134(1):A18425, 2016. e-Pub 2016.
23. Qazilbash MH, Thall P, Fox PS, Kebriaei P, Bashir Q, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Dinh Y, Hosing C, Popat UR, Lin P, Shah J, Orlowski RZ, Champlin RE. A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma. ASBMT 21(2), 2015.
24. Badar T, Parmar S, Cornelison AM, Shah N, Bashir Q, Patel K, Hosing C, Popat UR, Champlin RE, Qazilbash MH. Outcome of Patients with Systemic Light Chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. ASBMT 21(2), 2015.
25. Sasaki K, Saliba R, Lu G, Shah N, Bashir Q, Patel,K, Bock F, Parmar S, Hosing C, Uday R. Popat, Delgado R, Rondon G, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation. ASBMT 21(2), 2015.
26. Shah N, Li L, Kaur I, McCarty J, Yvon E, Shaim H, Muftuoglu M, Liu E, Sobieski C, Orlowski RZ, Cooper LJN, Lee DA, Parmar S, Cao K, Hosing CM, Ahmed S, Nieto Y, Bashir Q, Patel KK, Bollard CM, McNiece IK, Qazilbash M, Champlin RE, Rezvani K, Shpall EJ. Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study. ASH, 2015.
27. Khouri IF, Sui D, Turturro F, Erwin WD, Bassett Jr. RL, Korbling M, Valverde R, Ahmed S, Alousi AM, Anderlini P, Bashir Q, Ciurea SO, Oran B, Olson A, Popat UR, Patel KK, Qazilbash MH, Fanale MA, Fayad LE, Nastoupil L, Westin JR, Gulbis AM, Medeiros LJ, Young A, Jessop KH. In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. ASH, 2015.
28. Kebriaei P, Basset Jr. RL, Ledesma C, Rondon G, Oran B, Ciurea SO, Alousi AM, Popat UR, Patel KK, Ahmed S, Olson AL, Bashir Q, Shah N, Jones R, Rezvani K, Nieto Y, Khouri IF, Qazilbash MH, Hosing CM, Shpall EJ, Champlin RE, Andersson BS. Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results. ASH, 2015.
29. Ragon BK, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel KK, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit. ASH, 2015.
30. Khouri IF, Saliba RM, Ledesma C, Jabbour EJ, Turturro F, Alatrash G, Ahmed S, Oran B, Patel KK, Olson A, Marin D, Popat UR, Suki TS, Jorgensen JL, Medeiros LJ, Gulbis AM. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). ASH, 2015.
31. Claussen CM, Chuang T, Shah J, Lee H, Shah N, Patel KK, Bashir Q, Parmar S, Thomas S, Qazilbash M, Davis RE, Neelapu SS, Weber D, Orlowski RZ, Feng L, Manasanch EE. Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. ASH, 2015.
32. Patel K, Olivares S, Hurton, L, Huls H, Qazilbash M, Champlin R, Cooper LJN. T-Cell Therapy for Multiple Myeloma Using NY-ESO-1+ T-Cell Antigen Presenting Cells (T-APC) Combined with Adoptive Cellular Transfer (ACT) to Augment Immunotherapy. ASH 2014, 2014. e-Pub 2014.
33. Bock FM, Lu G, Shah N, Bashir Q, Patel KK, Popat UR, Hosing CM, Gaballa S, Korbling M, Delgado R, Rondon G, Orlowski RZ, Shah JJ, Manasanch EE, Champlin RE, Qazilbash MH. Clinical Characteristics and Outcomes in Patients with Multiple Myeloma and CKS1B Gene Gain/Amplification after Autologous Stem Cell Transplantation, 2014.
34. Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Patel,KK, Lin,P, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Phase I/II Trial of Lenalidomide and High Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma, 2014.
35. Patel K, Orlowski R, Qazilbash M, Shah J. Plasmablastic lymphoma: 28 patient single institution experience. ASH 2013, 2013. e-Pub 2013.
36. Nusrat M, Patel K. Fanconi Anemia Presenting with Symptomatic Pericardial Effusion. ACP Annual Meeting, 2013.
37. Patel K, Qazilbash M. Prognostic role of serum lactate dehydrogenase (LDH) prior to autologous stem cell transplant in Multiple Myeloma. ASH 2012, 2012.
38. Khan D, Patel K, Qazilbash M. Feasibility of Hematopoietic Stem Cell Collection and Cryopreservation in Waldenstrom’s Macroglobulinemia. ASH 2012, 2012.
39. Patel K, Saliba R, Qazilbash M. Autologous stem cell transplantation in Waldenstroms Macroglobulinemia. 2012 International Workshop on Waldenstrom's macroglobulinemia and Multiple Myeloma Symposium, 2012.
40. Patel K, Delasalle K, Orlowski R. Prognositic value of serum lactate dehydrogenase in symptomatic myeloma. ASCO 2012, 2011.
41. Koranne K, Patel K, Escobar M. Escobar M. Acquired Factor VIII inhibitor: a rare complication of Primary Biliary Cirrhosis. ACP Annual Meeting, 2011.
42. Richey S, Culp S, Jonash E, Corn P, Pagliaro L, Tamboli, Patel K, Matin S, Tannir N. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. ASCO 2011, 2011.

Book Chapters

1. Behrang Amini, Krina Patel, Richard M. Westmark, Kaye D. Westmark, and Anneliese Gonzalez. Approach to the Solitary Vertebral Lesio on Magnetic Resonance Imaging. In: Incidental Findings in Neuroimaging and Their Management: A Guide for Radiologists, Neurosurgeons, and Neurologists, 2020.
2. Patel K, Moyes J, Cooper LJN. Cell-based Cancer Immunotherapy. In: Cancer Medicine 9th edition, 2017.
3. Lee HC, Patel K, Kongtim P, Parmar S, Lin P, Qazilbash MH, Thomas S, Manasanch EE. Multiple Myeloma and Other Plasma Cell Dyscrasias. In: MD Anderson Manual for Medical Oncology, 2016.